Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors
Summary: Pancreatic ductal adenocarcinoma (PDAC) shows limited response to chemotherapy, partly due to the absence of effective biomarkers for personalized treatment. Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in 90% of PDAC cases, and tumors dependent on KRAS (dKRAS) can...
Saved in:
Main Authors: | Giorgia Anastasio, Michela Felaco, Alessia Lamolinara, Francesco del Pizzo, Elisa Cacciagrano, Carla Mottini, Margherita Mutarelli, Francesca Di Modugno, Manuela Iezzi, Luca Cardone |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | iScience |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004225001026 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC
by: Xiao-Mei Tang, et al.
Published: (2025-02-01) -
Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy
by: Pradyumna Agasthi, et al.
Published: (2018-01-01) -
Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor
by: Alessia Lamolinara, et al.
Published: (2015-01-01) -
PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparib
by: Xin‐Yuan Lei, et al.
Published: (2024-12-01) -
Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
by: Maya Gross, et al.
Published: (2022-01-01)